Interstitial Lung Disease News

SAN DIEGO — Taking an oral lysophosphatidic acid receptor 1 antagonist for 26 weeks slowed time to disease progression in idiopathic pulmonary fibrosis, according to a presentation at the American Thoracic Society International Conference.

SAN DIEGO — After receiving a hedgehog pathway inhibitor for 12 weeks, adults with idiopathic pulmonary fibrosis had better lung function, according to research presented at the American Thoracic Society International Conference.

SAN DIEGO — The absolute change in FVC at 48 weeks was similar between patients with idiopathic pulmonary fibrosis receiving pamrevlumab vs. placebo, according to a presentation at the American Thoracic Society International Conference.

DESTIN, Fla. — Detection and treatment of interstitial lung disease in systemic sclerosis calls for early and aggressive action, according to data presented at the Congress of Clinical Rheumatology East.

The diagnostic yield for interstitial lung disease was comparable between immediate surgical lung biopsy and a strategy that began with transbronchial cryobiopsy, according to results published in The Lancet Respiratory Medicine.

The odds for severe acute respiratory disease events rose among previous/current smokers with evidence of quantitative interstitial abnormality, or QIA, progression on CT scans, according to results published in Radiology.

Among hospitalized patients with various pulmonary conditions, living in a low socioeconomic status area heightened the odds for 30-day mortality and readmission, according to results published in Annals of the American Thoracic Society.

A tool that includes age, BMI, two lung function measures and a diagnosis of idiopathic pulmonary fibrosis can predict new-onset exertional and resting hypoxemia in fibrotic interstitial lung disease, according to study results.

Patients with idiopathic pulmonary fibrosis had less lung function decline with an oral c-Jun N-terminal kinase 1, or JNK, inhibitor vs. placebo, according to results published in American Journal of Respiratory and Critical Care Medicine.

Among patients with idiopathic pulmonary fibrosis, lung function decline was comparable between 52-week zinpentraxin alfa treatment and placebo, according to results published in American Journal of Respiratory and Critical Care Medicine.